Eurosurv. Evaluation of commercial and automated SARS-CoV-2 IgG and IgA ELISAs using coronavirus disease (COVID-19) patient samples

[tetano]

Evaluation of commercial and automated SARS-CoV-2 IgG and IgA ELISAs using coronavirus disease (COVID-19) patient samples

• Anne J J??skel?inen[SUP]1[/SUP], Eliisa Kek?l?inen[SUP]1[/SUP], Hannimari Kallio-Kokko[SUP]1[/SUP], Laura Mannonen[SUP]1[/SUP], Elisa Kortela[SUP]2[/SUP], Olli Vapalahti[SUP]1[/SUP], Satu Kurkela[SUP]1,3[/SUP], Maija Lappalainen[SUP]1,3[/SUP]

Antibody-screening methods to detect severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) need to be validated. We evaluated SARS-CoV-2 IgG and IgA ELISAs in conjunction with the EUROLabworkstation (Euroimmun, L?beck, Germany). Overall specificities were 91.9% and 73.0% for IgG and IgA ELISAs, respectively. Of 39 coronavirus disease patients, 13 were IgG and IgA positive and 11 IgA alone at sampling. IgGs and IgAs were respectively detected at a median of 12 and 11 days after symptom onset.

full article

https://www.eurosurveillance.org/content/10.2807/1560-7917.ES.2020.25.18.2000603#html_fulltext